In vivo pharmacological characterization of a novel selective α7 neuronal nicotinic acetylcholine receptor agonist ABT-107: Preclinical considerations in alzheimer's disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 3, 2010, Pages 875-886

  Bitner, R Scott ^a   Bunnelle, William H ^a   Decker, Michael W ^a   Drescher, Karla U ^b   Kohlhaas, Kathy L ^a   Markosyan, Stella ^a   Marsh, Kennan C ^a   Nikkel, Arthur L ^a   Browman, Kaitlin ^a   Radek, Rich ^a   Anderson, David J ^a   Buccafusco, Jerry ^c   Gopalakrishnan, Murali ^a  

^a ABBOTT LABORATORIES   (United States)

^b Alzheimer's Research Center Medical College of Georgia ^*

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [6 (1 AZABICYCLO[2.2.2]OCT 3 YLOXY)PYRIDAZIN 3 YL] 1H INDOLE; ABT 107; ACETYLCHOLINE; ACTIVATING TRANSCRIPTION FACTOR 2; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DONEPEZIL; GLYCOGEN SYNTHASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINE; NICOTINIC AGENT; TAU PROTEIN; UNCLASSIFIED DRUG; 5-(6-(1-AZABICYCLO(2,2,2)OCT-3-YLOXY)PYRIDAZIN-3-YL)-1H-INDOLE; AMYLOID PRECURSOR PROTEIN; BUNGAROTOXIN RECEPTOR; CHRNA7 PROTEIN, MOUSE; CHRNA7 PROTEIN, RAT; INDAN DERIVATIVE; INDOLE DERIVATIVE; NICOTINIC RECEPTOR; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE; QUINUCLIDINE DERIVATIVE;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; CINGULATE GYRUS; COGNITION; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG MECHANISM; ELECTROENCEPHALOGRAPHY; FEMALE; HIPPOCAMPUS; IN VIVO STUDY; LOCOMOTION; MALE; MAXIMUM PLASMA CONCENTRATION; MEMORY CONSOLIDATION; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PSYCHOMOTOR ACTIVITY; RAT; RECOGNITION; RHESUS MONKEY; SHORT TERM MEMORY; SOCIAL BEHAVIOR; WORKING MEMORY; ALZHEIMER DISEASE; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; METABOLISM; PERCEPTION; PHOSPHORYLATION; PSYCHOLOGY; PSYCHOMOTOR PERFORMANCE; SPRAGUE DAWLEY RAT; TOXICITY;

ACETYLCHOLINE; ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; COGNITION; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; ELECTROENCEPHALOGRAPHY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLYCOGEN SYNTHASE KINASE 3; INDANS; INDOLES; MACACA MULATTA; MALE; MICE; MICE, KNOCKOUT; NICOTINIC AGONISTS; NOOTROPIC AGENTS; PHOSPHORYLATION; PIPERIDINES; PSYCHOMOTOR PERFORMANCE; QUINUCLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; RECOGNITION (PSYCHOLOGY); SOCIAL PERCEPTION; TAU PROTEINS;

EID: 77956247430     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.167213     Document Type: Article

References (39)

1. Adams JP and Sweatt JD (2002) Molecular psychology: roles for the ERK MAP kinase cascade in memory. Annu Rev Pharmacol Toxicol 42:135-163.
2. Anderson DJ, Bunnelle W, Surber B, Du J, Surowy C, Tribollet E, Marguerat A, Bertrand D, and Gopalakrishnan M (2008) [3H]A-585539 [(1S,4S)-2,2-dimethyl- 5- (6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1]heptane], a novel high-affinity alpha7 neuronal nicotinic receptor agonist: radioligand binding characterization to rat and human brain. J Pharmacol Exp Ther 324:179-187.
3. Bartus RT (2000) On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163:495-529.
4. Benowitz NL (2009) Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol 49:57-71.
5. Berg DK and Conroy WG (2002) Nicotinic alpha 7 receptors: synaptic options and downstream signaling in neurons. J Neurobiol 53:512-523.
6. Bitner RS, Anderson DJ, Bunnelle WH, Briggs CA, Buccafusco J, Curzon P, Decker M, Gronlein H, Gubbins E, Haakerud M, et al. (2006) Broad spectrum efficacy in cognition by alpha7 neuronal nicotinic receptor activation of the MAP kinase pathway. Int J Neuropsychopharmacol 9 (Suppl. 1) S122.
7. Bitner RS, Bunnelle WH, Anderson DJ, Briggs CA, Buccafusco J, Curzon P, Decker MW, Frost JM, Gronlien JH, Gubbins E, et al. (2007) Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J Neurosci 27:10578-10587.
8. Bitner RS, Nikkel AL, Markosyan S, Otte S, Puttfarcken P, and Gopalakrishnan M (2009) Selective alpha7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3beta and decreases tau phosphorylation in vivo. Brain Res 1265:65-74.
9. Bondy CA and Cheng CM (2004) Signaling by insulin-like growth factor 1 in brain. Eur J Pharmacol 490:25-31.
10. Buccafusco JJ and Terry AV (2004) Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys. J Mol Neurosci 24:85-91.
11. Buccafusco JJ, Terry AV Jr, and Murdoch PB (2002) A computer-assisted cognitive test battery for aged monkeys. J Mol Neurosci 19:179-185.
12. Buckingham SD, Jones AK, Brown LA, and Sattelle DB (2009) Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol Rev 61:39-61.
13. Chong ZZ, Li F, and Maiese K (2005) Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury. Histol Histopathol 20: 299-315.
14. Clarke PB and Kumar R (1983) The effects of nicotine on locomotor activity in non-tolerant and tolerant rats. Br J Pharmacol 78:329-337.
15. Connor B, Young D, Yan Q, Faull RL, Synek B, and Dragunow M (1997) Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res Mol Brain Res 49:71-81.
16. Coyle JT, Price DL, and DeLong MR (1983) Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219:1184-1190.
17. Dalley JW, Cardinal RN, and Robbins TW (2004) Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav Rev 28:771-784.
18. Germano C and Kinsella GJ (2005) Working memory and learning in early Alzheimer's disease. Neuropsychol Rev 15:1-10.
19. Giacobini E and Becker RE (2007) One hundred years after the discovery of Alzheimer's disease. A turning point for therapy? J Alzheimers Dis 12:37-52.
20. Giovannini MG (2006) The role of the extracellular signal-regulated kinase pathway in memory encoding. Rev Neurosci 17:619-634.
21. Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, and Arancio O (2004) Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 114:1624-1634.
22. Hu M, Waring JF, Gopalakrishnan M, and Li J (2008) Role of GSK-3beta activation and alpha7 nAChRs in Abeta(1-42)-induced tau phosphorylation in PC12 cells. J Neurochem 106:1371-1377.
23. Ji J (2007), inventor. Abbott Laboratories, assignee. Fused bicycloheterocycle substituted quinuclidine derivatives. U.S. Patent 7,160,876 B2. 2007 Jan 9.
24. Kelley BJ and Petersen RC (2007) Alzheimer's disease and mild cognitive impairment. Neurol Clin 25:577-609.
25. Leiser SC, Bowlby MR, Comery TA, and Dunlop J (2009) A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol Ther 122:302-311.
26. Levin ED, Briggs SJ, Christopher NC, and Rose JE (1992) Persistence of chronic nicotine-induced cognitive facilitation. Behav Neural Biol 58:152-158.
27. Levin ED, Petro A, Rezvani AH, Pollard N, Christopher NC, Strauss M, Avery J, Nicholson J, and Rose JE (2009) Nicotinic alpha7- or beta2-containing receptor knockout: effects on radial-arm maze learning and long-term nicotine consumption in mice. Behav Brain Res 196:207-213.
28. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, et al. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487-1491.
29. Malysz J, Anderson DJ, Gronlien JH, Ji J, Bunnelle WH, Hakerud M, Thorin-Hagene K, Ween H, Helfrich R, Hu M, et al. (2010) In vitro pharmacological characterization of a novel selective α7 neuronal nicotinic acetylcholine receptor agonist ABT-107. J Pharmacol Exp Ther 334:875-886.
30. Marrero MB, Papke RL, Bhatti BS, Shaw S, and Bencherif M (2004) The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo[3.2.2]nonane (TC-1698), a novel alpha7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase. J Pharmacol Exp Ther 309:16-27.
31. Mudo G, Belluardo N, and Fuxe K (2007) Nicotinic receptor agonists as neuroprotective/ neurotrophic drugs. Progress in molecular mechanisms. J Neural Transm 114:135-147.
32. Pallàs M and Camins A (2006) Molecular and biochemical features in Alzheimer's disease. Curr Pharm Des 12:4389-4408.
33. Picciotto MR, Zoli M, Rimondini R, Léna C, Marubio LM, Pich EM, Fuxe K, and Changeux JP (1998) Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391:173-177.
34. Ring RH, Alder J, Fennell M, Kouranova E, Black IB, and Thakker-Varia S (2006) Transcriptional profiling of brain-derived-neurotrophic factor-induced neuronal plasticity: a novel role for nociceptin in hippocampal neurite outgrowth. J Neurobiol 66:361-377.
35. Rogers SL, Cooper NM, Sukovaty R, Pederson JE, Lee JN, and Friedhoff LT (1998) Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol 46 (Suppl. 1):7-12.
36. Seltzer B (2005) Donepezil: a review. Expert Opin Drug Metab Toxicol 1:527-536.
37. Shaw S, Bencherif M, and Marrero MB (2002) Janus kinase 2, an early target of alpha 7 nicotinic acetylcholine receptor-mediated neuroprotection against Abeta- (1-42) amyloid. J Biol Chem 277:44920-44924.
38. Stolerman IP, Garcha HS, and Mirza NR (1995) Dissociations between the locomotor stimulant and depressant effects of nicotinic agonists in rats. Psychopharmacology 117:430-437.
39. Yamamoto-Sasaki M, Ozawa H, Saito T, Rösler M, and Riederer P (1999) Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type. Brain Res 824:300-303.